Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic Proteomic and Pharmacogenomic Correlative Study.
Research Study on Investigational Treatment for [Condition]
Not Recruiting
18 years - 100 years
Female
Phase
N/A
Brief description of study.
No Description Available
Detailed description of study
No Description Available
Eligibility of study
You may be eligible for this study if you meet the following criteria:
Conditions:Breast Cancer
Age:
18 years - 100 years
Gender: Female
Who can participate: Individuals aged [age range] with a diagnosis of [condition] may be eligible. Key inclusion criteria include [list key criteria].
Study details: Participants will receive either the investigational treatment or a placebo, administered [frequency]. They will be required to attend [number] visits for assessments and monitoring.
Updated on
19 Feb 2024.
Study ID: 0808-09
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
